The Latest Cardiac and Vascular News
PARIS, May 22, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced 30-day data demonstrating that treatment with the Edwards SAPIEN 3 valve in more than 450 commercial centers around the U.S. show consistently positive patient outcomes. The […]
PARIS, May 21, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced key events for the company during EuroPCR 2018, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of […]
IRVINE, Calif., May 1, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced today that it entered into an accelerated share repurchase (ASR) agreement to repurchase an aggregate of $400 million of Edwards’ common stock. Under the terms of this ASR agreement, […]
MARLBOROUGH, Mass., March 28, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the U.K. Court of Appeal dismissed Edwards Lifesciences‘ appeal and upheld a prior court decision that Edwards’ Sapien 3™ device infringes Boston Scientific patent EP (UK) 2 926 766 and that all claims of that patent are valid. “We […]
IRVINE, Calif., June 5, 2017 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it has received U.S. Food and Drug Administration (FDA) approval for aortic and mitral valve-in-valve procedures using the Edwards SAPIEN 3 transcatheter heart valve. […]
